|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WAPAL |
Gene summary for WAPAL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WAPAL | Gene ID | 23063 |
| Gene name | WAPL cohesin release factor | |
| Gene Alias | FOE | |
| Cytomap | 10q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | A8K273 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23063 | WAPAL | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 1.86e-05 | 6.96e-01 | 0.1557 |
| 23063 | WAPAL | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 2.22e-03 | 5.58e-01 | 0.159 |
| 23063 | WAPAL | GSM5353217_PA_PB1A_Pool_2_S107_L004 | Human | Prostate | Tumor | 4.29e-06 | 8.24e-01 | 0.156 |
| 23063 | WAPAL | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 1.55e-02 | 4.18e-01 | 0.1479 |
| 23063 | WAPAL | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.17e-23 | 7.28e-01 | 0.1633 |
| 23063 | WAPAL | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 5.61e-19 | 5.77e-01 | 0.1608 |
| 23063 | WAPAL | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 7.31e-18 | 6.13e-01 | 0.1604 |
| 23063 | WAPAL | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.97e-14 | 4.68e-01 | 0.1621 |
| 23063 | WAPAL | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 2.50e-07 | 5.53e-01 | 0.1619 |
| 23063 | WAPAL | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.61e-11 | 4.88e-01 | 0.1602 |
| 23063 | WAPAL | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 5.74e-06 | 5.47e-01 | 0.1608 |
| 23063 | WAPAL | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.14e-06 | 5.19e-01 | 0.1622 |
| 23063 | WAPAL | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.26e-15 | 5.40e-01 | 0.1575 |
| 23063 | WAPAL | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 3.90e-06 | 3.31e-01 | 0.1545 |
| 23063 | WAPAL | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 6.37e-10 | 5.02e-01 | 0.1569 |
| 23063 | WAPAL | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 2.45e-02 | 5.90e-01 | 0.1541 |
| 23063 | WAPAL | P1_S1_AK | Human | Skin | AK | 1.90e-03 | -1.12e-01 | -0.3399 |
| 23063 | WAPAL | P2_S3_AK | Human | Skin | AK | 8.97e-04 | -1.12e-01 | -0.3287 |
| 23063 | WAPAL | P2_S4_SCCIS | Human | Skin | SCCIS | 8.97e-04 | -1.12e-01 | -0.3043 |
| 23063 | WAPAL | P3_S6_AK | Human | Skin | AK | 1.90e-03 | -1.12e-01 | -0.3256 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04110 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
| hsa041101 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa041104 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa0411011 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411041 | Oral cavity | EOLP | Cell cycle | 42/1218 | 157/8465 | 3.20e-05 | 1.61e-04 | 9.52e-05 | 42 |
| hsa0411051 | Oral cavity | EOLP | Cell cycle | 42/1218 | 157/8465 | 3.20e-05 | 1.61e-04 | 9.52e-05 | 42 |
| hsa0411061 | Oral cavity | NEOLP | Cell cycle | 37/1112 | 157/8465 | 2.29e-04 | 1.58e-03 | 9.95e-04 | 37 |
| hsa0411071 | Oral cavity | NEOLP | Cell cycle | 37/1112 | 157/8465 | 2.29e-04 | 1.58e-03 | 9.95e-04 | 37 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |